Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond
June 23 2022 - 7:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its Chief Executive
Officer, Dr. Tiago Reis Marques, will participate in the H.C.
Wainwright 1st Annual Mental Health Conference: Neuropsychiatry,
Psychedelics and Beyond, as follows:
Date: |
Monday, June 27, 2022 |
Time: |
10:30 a.m. ET |
Location: |
The Lotte New York Palace Hotel |
Investors participating in the conference who would like to
schedule a one-on-one meeting with Pasithea’s CEO may do so by
contacting their H.C. Wainwright representative or registering
HERE.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S. biotechnology
company focused on the research and discovery of new and effective
treatments for psychiatric and neurological disorders. With an
experienced team of experts in the fields of neuroscience and
psychopharmacology, Pasithea is developing new molecular entities
for the treatment of psychiatric and neurological disorders.
Pasithea is also focused on addressing the needs of patients
currently suffering with mental illness by providing access to IV
ketamine infusions both in clinics and in-home settings.
Pasithea Therapeutics Corp. Company
ContactDr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jul 2023 to Jul 2024